On Monday, a group representing the American Association for Cancer Research (AACR), the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO) and the National Cancer Institute (NCI) released a position statement, “Charting the Future of Cancer Health Disparities Research.” It spells out why cancer health disparities continue to drive late diagnoses and bad outcomes for so many and offers an ambitious list of needs, priorities and recommendations — a research roadmap, if you will — to help even the playing field.
The paper was published simultaneously in AACR's journal, Cancer Research; ASCO’s Journal of Clinical Oncology, the ACS’s CA: A Cancer Journal for Clinicians and on the NCI’s website. Its authors — leaders in clinical research, public health, epidemiology and patient advocacy — are members of a think tank created two years ago to foster better cooperation across the cancer research community.
“As far as I know, a partnership like this across these organizations is unprecedented,” said Dr. Christopher Li, a public health researcher with Fred Hutchinson Cancer Research Center, and a co-author on the paper. “It speaks to the importance of the issues involved that all of these organizations would make it a priority to come together and publish a statement with a unified voice.”
Getting granular about patient data
The expansive report addressed a wide range of issues and potential solutions. One of the biggest stumbling blocks in health disparities research, the report concluded, is data. There’s not nearly enough of it and there’s no consistency with regard to what’s gathered.
Patient data is frequently spotty or oversimplified. Questions about socioeconomic status or health literacy often go unasked. Large biospecimen banks devoted to people of color are nearly nonexistent. And even some of what is gathered isn’t necessarily all that useful. Overarching categories like Hispanic, Asian and African-American don’t accurately reflect our blended society, Li said, nor do they offer the kind of genetic insights that could better guide health choices and cancer treatment.
”The field of health disparities as it relates to cancer has evolved,” he said. “It began with looking at ‘black-white’ differences, but it’s become so much more nuanced as we’ve started to really appreciate all the diversity that exists in our country.”
Within given racial/ethnic categories, for instance, the data need to be more granular. An umbrella term like “Hispanic” might include someone of Mexican descent, Cuban American descent, South American descent, a third generation Hispanic American or a recent immigrant, he said.
“Race and ethnicity are social constructs,” he said. “And there can be quite a bit of heterogeneity within broad racial groups. Someone may self-identify as part of one group but there’s a genetic piece that allows us to really see where their ancestry falls and how that relates to cancer incidence and cancer outcomes and survivorship.”
Today, cancer researchers and clinicians need to look not only at race but at ethnicity, socioeconomic status, neighborhoods, ancestry, immigration status and lifestyle factors. They need to dive deep, asking questions about everything from literacy to gender identity to the availability of healthy food.
“We need to appreciate that disparities can be defined on multiple levels,” he said, “as factors on the individual, neighborhood, county, and state levels can all play a role.”